Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma

Completed · Phase 1

Conditions studied: Leukemia, Lymphoma

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of bryostatin 1 and high dose cytarabine in treating patients with refractory or relapsed acute myelocytic or acute lymphocytic leukemia, chronic myelogenous leukemia or refractory or relapsed lymphoblastic lymphoma.

Key facts

Study ID

NCT00003079

Run by

Virginia Commonwealth University

People needed

30

Starts

1997-09-01

Expected to finish

2001-05-01

Last updated by the study team

2010-02-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• New York Presbyterian Hospital - Cornell Campus — New York, New York, United States
• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States
• Massey Cancer Center — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.